Neumora Therapeutics, an early-stage neuroscience drug development company, focuses on three key areas, alzheimer's agitation, schizophrenia and obesity. The companies three lead candidates, will have early stage clinical trial read-outs, by the end of 2026.
Financial Statistics:
- $147 million cash
- 180 million diluted shares outstanding
- 270 million market cap
- 180 million diluted shares outstanding
- 270 million market cap
Intellectual Property:
- NMRA - 511 Alzheimer's Agitation, Expected to expire into 2042
- NMRA - 898 Schizophrenia, Expected to expire in 2044
- NMRA - 215 Obesity, Expected to expire in 2043
Timeline Catalyst:
- NMRA-511: Multiple ascending dose completion in the fourth quarter 2026
- NMRA-898: Phase 1 data 2H of 2026
- NMRA-215: Start clinical trials by end of 2026
Neumora is a clinical stage biotech company focused on three areas of unmet need. The stock is priced at $1.51 per share (penny stock). There are many risks to investing in this company.
Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.
